This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kawasaki, T. Articles by Kambayashi, J.-i. Search for Related Content PubMed PubMed Citation Articles by Kawasaki, T. Articles by Kambayashi, J.-i. Related Collections Cardiovascular Pharmacology Cell signalling/signal transduction Antiplatelets Platelets

(Stroke. 2000;31:591.)
© 2000 American Heart Association, Inc.

Original Contribution

Increased Platelet Sensitivity to Collagen in Individuals Resistant to Low-Dose Aspirin

Tomio Kawasaki, MD, PhD; Yasushi Ozeki, PhD; Takehiro Igawa, PhD Jun-ichi Kambayashi, MD, PhD

From the Department of Surgery 2, Osaka University Medical School, Osaka, Japan (T.K.); Thrombosis and Vascular Research Laboratory, Otsuka Pharmaceutical Co, Ltd, Tokushima, Japan (Y.O.); and Maryland Research Laboratories, Otsuka America Pharmaceutical, Inc, Rockville (T.I., J-i.K.).

Correspondence to Tomio Kawasaki, Department of Surgery 2, Osaka University Medical School, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan. E-mail kawasaki{at}surg2.med.osaka-u.ac.jp

Background and Purpose—The purpose of this study was to assess individual differences in the pharmacological effects of acetylsalicylic acid (ASA) on bleeding time as measured by in vitro platelet aggregation and to examine the consistency of responses over time.

Methods—We measured template IIR bleeding time and platelet aggregation in 8 healthy male volunteers before and 2 hours after ingestion of 324 mg of ASA. An individual was considered a nonresponder if his post-ASA bleeding time was not 2 SDs above his baseline bleeding time, where SD was estimated from the baseline bleeding times of the 8 volunteers. The same experiment was done after a 30-month interval.

Results—Five volunteers were identified as ASA responders, and 3 were identified as nonresponders. Bleeding time before and after ingestion of ASA was 408±121 seconds (mean±SD) and 720±225 seconds, respectively, in ASA responders and 330±30 seconds and 330±52 seconds, respectively, in ASA nonresponders. The mean ED₅₀ for collagen-induced platelet aggregation, that is, the mean concentration of collagen that caused a response at 50% of maximum, was 0.91 µg/mL (95% CI, 0.73 to 1.14) in ASA responders and 0.48 µg/mL (95% CI, 0.38 to 0.60) in nonresponders. When optimum concentrations of collagen, ie, concentrations that yielded 90% maximum aggregation, were used as stimuli, the mean IC₅₀ for ASA, that is, the mean concentration that yielded 50% inhibition, was 322.5 µmol/L (95% CI, 264.8 to 392.6) in ASA responders and 336.1 µmol/L (95% CI, 261.0 to 432.8) in nonresponders. The variability in individual responsiveness in the second experiment remained consistent with that in the first experiment.

Conclusions—ASA resistance may be caused by an increased sensitivity of platelets to collagen. A platelet aggregation study specific for collagen dose response may be useful for strict selection of ASA responders for low-dose ASA therapy and for identifying ASA nonresponders for high-dose ASA therapy.

Key Words: aspirin • bleeding time • collagen • platelets

This article has been cited by other articles:

				G. Krasopoulos, S. J Brister, W S. Beattie, and M. R Buchanan Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis BMJ, January 26, 2008; 336(7637): 195 - 198. [Abstract] [Full Text] [PDF]

				E. I. Lev, R. T. Patel, K. J. Maresh, S. Guthikonda, J. Granada, T. DeLao, P. F. Bray, and N. S. Kleiman Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention: The Role of Dual Drug Resistance J. Am. Coll. Cardiol., January 3, 2006; 47(1): 27 - 33. [Abstract] [Full Text] [PDF]

				E. I. Lev, R. T. Patel, K. J. Maresh, S. Guthikonda, J. Granada, T. DeLao, P. F. Bray, and N. S. Kleiman Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention: The Role of Dual Drug Resistance J. Am. Coll. Cardiol., December 13, 2005; (2005) j.jacc.2005.08.058v1. [Abstract] [Full Text] [PDF]

				P. J. Mason, A. K. Jacobs, and J. E. Freedman Aspirin Resistance and Atherothrombotic Disease J. Am. Coll. Cardiol., September 20, 2005; 46(6): 986 - 993. [Abstract] [Full Text] [PDF]

				M. Cattaneo Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 1980 - 1987. [Abstract] [Full Text] [PDF]

				A. Lepantalo, K. S Virtanen, J. Heikkila, U. Wartiovaara, and R. Lassila Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions Eur. Heart J., March 2, 2004; 25(6): 476 - 483. [Abstract] [Full Text] [PDF]

				J. W. Eikelboom and G. J. Hankey Aspirin resistance:a new independent predictor of vascular events? J. Am. Coll. Cardiol., March 19, 2003; 41(6): 966 - 968. [Full Text] [PDF]

				M. Friend, I. Vucenik, and M. Miller Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia BMJ, January 11, 2003; 326(7380): 82 - 83. [Full Text] [PDF]